Contributions
Abstract: 9
Type: Educational Session
Abstract Category: N/A
Recently, treatment guidelines for multiple sclerosis have become available in Europe and North America. The strategies to prevent MS-related disability are becoming more clearly defined, including early commencement of immunotherapy selected from a broad range of available agents, therapies for progressive disease forms, individualised approach to treatment, and close monitoring of patients' neurological status and of treatment effectiveness and safety. While many of these recommendations are based on observations from randomised trials, a large body of new evidence is emerging, in particular from observational registries. This session will cover the emerging knowledge about individual variation in treatment effectiveness, severe multiple sclerosis and salient markers that help guide MS therapy more efficiently.
Disclosure: Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen.
Abstract: 9
Type: Educational Session
Abstract Category: N/A
Recently, treatment guidelines for multiple sclerosis have become available in Europe and North America. The strategies to prevent MS-related disability are becoming more clearly defined, including early commencement of immunotherapy selected from a broad range of available agents, therapies for progressive disease forms, individualised approach to treatment, and close monitoring of patients' neurological status and of treatment effectiveness and safety. While many of these recommendations are based on observations from randomised trials, a large body of new evidence is emerging, in particular from observational registries. This session will cover the emerging knowledge about individual variation in treatment effectiveness, severe multiple sclerosis and salient markers that help guide MS therapy more efficiently.
Disclosure: Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen.